Liquid Biopsy Market Growth Analysis By Top Key Players: Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG , Bio-Rad Laboratories Inc., Myriad Genetics , Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.

Global Liquid Biopsy Market was valued at $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of the cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumor genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients. The advantages of liquid biopsy over solid tumor biopsy, rise in awareness about minimally invasive procedures, favorable government initiatives, and presence of huge cancer population base are major factors that drive the market growth.

Download PDF Sample Report @ https://www.alliedmarketresearch.com/request-sample/1891

The global liquid biopsy market is segmented based on product & service, circulating biomarker, cancer type, end user, and geography. Based on product & service, it is categorized into reagents, instruments and services. On the basis of circulating biomarker, it is classified into circulating tumor cells, circulating tumor DNA, extracellular vesicles and other biomarkers. The market is studied across different cancer types, such as lung, breast, colorectal, prostate, liver, and other cancers. Based on end user, it is bifurcated into hospitals & laboratories and government & academic research centers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market is expected to witness a moderate growth during the forecast period, owing to the benefits offered by liquid biopsies over solid tissue biopsy methods. Furthermore, surge in prevalence of cancer and rise in awareness about minimally invasive methods among the patient pool are anticipated to augment the market growth. The increase in pre-screening programs for cancer detection is expected to present various opportunities for market expansion. However, alternatives to liquid biopsies and unclear reimbursement & regulation scenario are expected to hamper the market growth.

The report provides extensive competitive analysis and profiles of key market players, such as

Biocept, Inc.,
Qiagen,
F. Hoffmann-La Roche AG,
Bio-Rad Laboratories Inc.,
Myriad Genetics,
Janssen Diagnostics, LLC.,
Trovagene Inc.,
Guardant Health Inc.,
GRAIL, and MDX Health SA.

The other players in the value chain include Fraunhofer-Gesellschaft, Horizon Discovery, Illumina, Inc., Cynvenio, Diagnologix, Exosome Sciences, and CyoTrack.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/1909

Key Findings of the Liquid Biopsy Market:

- The government & academic research center segment is projected to grow at the highest rate during the analysis period.

- Hospital & laboratory segment was the highest revenue-generating segment, and is expected to continue its dominance in future.

- North America dominated global liquid biopsy market, and is projected to grow at a CAGR of 28.1%.

- China is expected to grow at the highest CAGR of 34.1% in Asia-Pacific region.

- The instruments segment is anticipated to grow at the highest CAGR of 29.8% during the forecast period.

For More Information @ https://www.alliedmarketresearch.com/liquid-biopsy-market

Table of Content


Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Increase in demand for safe and non-invasive procedures
3.6.1.2. Surge in the global prevalence rate of cancer
3.6.1.3. Advantages of liquid biopsy tests over traditional tests

3.6.2. Restraints

3.6.2.1. Limitations associated with liquid biopsy testing
3.6.2.2. Lack of awareness in developing and underdeveloped regions

3.6.3. Opportunities

3.6.3.1. Use of liquid biopsy for treatment of rare cancer
3.6.3.2. Untapped potential of emerging markets

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.